Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)

Brief description of study

The purpose of this randomized, open-label, 2-arm, Phase 3 study is to assess the assess the
efficacy, safety and tolerability of rovalpituzumab tesirine versus topotecan in participants
with advanced or metastatic Small Cell Lung Cancer (SCLC) with high levels of delta-like
protein 3 (DLL3) and who have first disease progression during or following front-line
platinum-based chemotherapy.